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Systematic Strategy of Prophylactic Coronary
Angiography Improves Long-Term Outcome After
Major Vascular Surgery in Medium- to High-Risk Patients
A Prospective, Randomized Study
Mario Monaco, MD,* Paolo Stassano, MD,‡ Luigi Di Tommaso, MD,‡ Paolo Pepino, MD,*
Arturo Giordano, MD,† Giovanni B. Pinna, MD,‡ Gabriele Iannelli, MD,‡
Giuseppe Ambrosio, MD, PHD§
Castelvolturno, Naples, and Perugia, Italy
Objectives This study was undertaken to determine the impact of a strategy of systematic coronary angiography on
immediate- and long-term outcome of patients at medium-high risk who were undergoing surgical treatment of
peripheral arterial disease.
Background Despite pre-operative risk stratification according to the current guidelines, vascular surgery patients still repre-
sent a high-risk population, as 30-day cardiovascular complications and mortality rates still remain as high as
15% to 20% and 3% to 5%, respectively.
Methods In all, 208 consecutive patients scheduled for elective surgical treatment of major vascular disease and with a revised
cardiac risk index 2 were randomly allocated to either a “selective strategy” group (group A, n  103), in whom
coronary angiography was performed based on the results of noninvasive tests, or to a “systematic strategy” group
(group B, n  105), consisting of patients who systematically underwent pre-operative coronary angiography.
Results The 2 groups were similar with respect to baseline clinical characteristics, revised cardiac risk index, and type of
vascular surgery performed. The myocardial revascularization rate in group B was higher than in group A (58.1%
vs. 40.1%; p  0.01). In-hospital major adverse cardiovascular event rate was not significantly lower in group B
(p  0.07). At 58  17 months of follow-up, group B showed significantly better survival (p  0.01) and free-
dom from death/cardiovascular events (p  0.003).
Conclusions In this study, a strategy of routine coronary angiography positively impacted long-term outcome of peripheral
arterial disease surgical patients at medium-high risk. This is the first such demonstration in a randomized, pro-
spective trial. Multicenter trials to confirm this finding in a larger population are warranted. (J Am Coll Cardiol
2009;54:989–96) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.041b
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che extent and severity of atherosclerotic lesions in major
eripheral artery vessels correlate with the extent and
everity of coronary artery disease (CAD) (1–4). Among
atients undergoing major surgery for peripheral artery
isease (PAD), the prevalence of CAD ranges from 37% to
8%, and myocardial infarction (MI) is the main cause of
erioperative death (5,6). As a consequence, it is thought by
any that these patients should be outright considered
andidates for coronary angiography and possible coronary
evascularization. Indeed, coronary artery revascularization
rom the *Unit of Cardiovascular Surgery and †Interventional Cardiology, Istituto
linico Pineta Grande, Castelvolturno, Italy; ‡Unit of Cardiac Surgery, University
Federico II” Medical School, Naples, Italy; and the §Division of Cardiology,
niversity of Perugia Medical School, Perugia, Italy.r
Manuscript received December 29, 2008; revised manuscript received May 4, 2009,
ccepted May 11, 2009.efore elective major vascular surgery has been advocated to
educe perioperative mortality rate (7,8). However, this issue
s still hotly debated, as 2 recent randomized studies have
hown that, among patient candidates for major vascular
See page 997
urgery, coronary artery revascularization before vascular sur-
ery was not associated with an improved outcome (9,10). In
he American Heart Association (AHA)/American College of
ardiology (ACC) guideline update, coronary angiography is
ecommended only if the patient, after positive noninvasive
esting, is considered at increased risk for perioperative cardiac
omplications (11).
According to current guidelines, pre-operative coronary
isk assessment is best achieved—in patients with 2 or more
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Coronary Angiography Before Vascular Surgery September 8, 2009:989–96risk factors by Lee’s revised cardiac
risk index (RCRI)—by means of
noninvasive testing (11,12). How-
ever, despite pre-operative risk
stratification according to the
guidelines, vascular surgery pa-
tients still represent a high-risk
population, as 30-day cardiovascu-
lar complication rates and mortal-
ity rates still remain as high as 15%
to 20% and 3% to 5%, respectively
(13). Thus, current recommenda-
tions seem to underestimate the
true incidence of CAD. Further-
more, it has long been held that
pre-treatment with beta-blockers
would dramatically reduce inci-
dence of perioperative cardiac
complications, thus making exten-
sive pre-operative work-up unnec-
essary (14–16); however, this no-
tion has recently been seriously
challenged (17–20).
Therefore, we are left with little
guidance on how to best manage
these patients pre-operatively, and
thus there is a need for an effective
strategy to curb their risk of cardiac
events.
With this aim, we designed a
protocol to test whether for pa-
ients with RCRI 2 and in need of peripheral vascular
ngiography before major vascular surgery, a systematic
trategy of routinely performed pre-operative coronary an-
iography would be more effective in reducing the occur-
ence of major adverse cardiovascular events (MACE) than
strategy based on selective coronary angiography guided by
he results of noninvasive tests. Patients scheduled to
ndergo elective major vascular surgery were randomly and
rospectively enrolled, and followed up for at least 3 years.
ethods
tudy population. From January 2000 through December
004, 672 consecutive patients were admitted for elective
ajor vascular surgery, aortoiliac obstructive disease, or
bdominal aortic aneurysm (AAA) repair. Diagnosis was
ade by echo-duplex scanner and/or spiral computed to-
ography. Surgical indications for AAA were dimension
5 cm, and for aortoiliac obstructive disease, the indication
as a stenosis 75% of the aortic bifurcation and/or of the
liac arteries, not suitable to percutaneous repair. All pa-
ients were administered statins, beta-blockers, and low-
olecular-weight heparin 1 week before admission, discon-
inuing antiplatelet therapy. The study was approved by the
Abbreviations
and Acronyms
AAA  abdominal aortic
aneurysm
ACC  American College
of Cardiology
AHA  American Heart
Association
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
DSE  dobutamine stress
echocardiography
dTS  dipyridamole-
thallium scintigraphy
OPCABG  off-pump
coronary artery bypass
graft surgery
MACE  major adverse
cardiovascular event
MI  myocardial infarction
NYHA  New York Heart
Association
PAD  peripheral artery
disease
RCRI  revised cardiac
risk indexthics committee of all institutions. bAfter a thorough medical and instrumental evaluation,
08 patients were found to have a RCRI 2 (12), and they
orm the basis of this trial. In all of these patients, the
eta-blocker regimen was titrated to achieve a resting heart
ate of 60 beats/min. After a detailed description of the
rocedure and having obtained written informed consent,
atients were allocated through a computer-generated ran-
omization list into 2 groups. The “selective strategy” group
consisted of 103 patients who eventually underwent
oronary angiography at the time of peripheral angiography
s a result of a positive stress test (see the following text for
etails), according to current guidelines (21). The “system-
tic strategy” group B consisted of 105 patients who
nderwent outright coronary angiography at the time of
eripheral angiography, without a noninvasive test being
erformed.
ardiac testing. Left ventricular ejection fraction was as-
essed by resting echocardiographic images using biplane
impson’s rule. Cardiac stress testing was performed by
ipyridamole-thallium scintigraphy (dTS) or dobutamine
tress echocardiography (DSE). All 103 group A patients
nderwent pre-operative testing during hospital admission.
he DSE or dTS was performed according to availability:
TS was performed in 55 patients (56.3%), and DSE was
erformed in 48 (43.7%, p 0.4). Positivity was considered
o be the appearance of 1 or more reversible thallium-201
yocardial defects for dTS and the occurrence or worsening
f wall motion abnormalities in at least 2 adjacent segments
or DSE.
ngiographic strategy. Peripheral angiography was per-
ormed in all patients as part of a routine diagnostic workup
efore major vascular surgery to confirm vascular pre-
perative noninvasive testing and/or to gain additional
natomical information (e.g., location of aneurysmal neck in
AA patients). In all patients for whom coronary angiog-
aphy was indicated, coronary and peripheral vascular an-
iography were performed at the same time and by the same
eam. Stenoses of 70% of major epicardial vessels (50%
or left main trunk) were considered significant. A patient
as considered eligible for myocardial revascularization
rocedure if 1 or more major coronary vessels, suitable for
evascularization, showed a significant stenosis.
oronary revascularization strategy. A staged approach
myocardial revascularization followed by vascular surgery)
as typically performed. Combined procedures (i.e., repair
f AAA immediately after myocardial revascularization
rocedure in the same surgical session) were reserved only
or patients with large aortic aneurysms (6 cm) and/or
igns of impending rupture. Percutaneous coronary inter-
entions were performed at the time of coronary angiogra-
hy, using bare metal stents. Patients were then discharged
n a double antiplatelet regimen of 75 mg/day clopidogrel
r 250 mg/day ticlopidine, plus 100 mg/day aspirin, and
ere scheduled for vascular surgery within 30 to 60 days.
nly clopidogrel or ticlopidine were withdrawn 7 daysefore surgery. When surgical revascularization was indicated,
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September 8, 2009:989–96 Coronary Angiography Before Vascular Surgeryhe off-pump coronary artery bypass graft (OPCABG) tech-
ique was always employed, and a 30- to 60-day interproce-
ure interval was observed.
tudy end points. Patients were followed up for at least 3
ears after surgery, and the primary end point was the
ACE incidence at follow-up; the occurrence of a MACE
etween the screening and 30 days after the index surgical
rocedure was considered as the secondary end point. The
ACE definitions are given in Table 1.
ollow-up. Follow-up data were obtained directly from
he patients and/or their family physician by telephone call
r by written questionnaire, at 30 days if a patient had been
ischarged from the hospital and every 6 months thereafter.
ata collected included death, functional status according
o New York Heart Association (NYHA) functional clas-
ification, and anginal status according to the Canadian
ardiovascular Society (CCS) classification, as well as any
ew MACE.
tatistical analysis. As previously reported, the CARP
Coronary Artery Revascularization Prophylaxis) trial (9)
hows a mortality of 22% in the revascularization group and
3% in the no-revascularization group, at a median of 2.7
ears after randomization, and an incidence of MACE can
e observed in 20% of cases within 30 days after major
ascular surgery. Therefore, our study enrolled a total
ample of 200 patients to observe a 10% reduction in
ong-term and 30-day MACE rate, with a statistical power
f 80% (1  beta) to detect a probability of 0.05 (alpha
rror level). All variables are presented as mean and standard
eviation. The chi-square test for categorical variables and
he Mann-Whitney test for continuous data were used to
ssess statistical significance. Differences resulting in a
value 0.05 were considered significant. Intention-to-
reat analyses provided information about survival from the
ime of randomization. If more than 1 end point occurred
efinitionsTable 1 Definitions
Nonfatal myocardial
infarction
Myocardial infarction after coronary artery bypass
graft surgery or percutaneous coronary
intervention was defined as a creatine kinase-
MB rise 3 times the upper limit of normal.
Myocardial infarction within 30 days after the
index surgical procedure was defined as a
troponin-T level 2 times the upper limit of
normal, in combination with new Q waves on
the electrocardiogram lasting 0.03 s. In all
other situations, myocardial infarctions were
defined by new Q waves lasting 0.03 s.
Cerebrovascular
accident
Any new episode of transient ischemic attack
or stroke.
Congestive heart
failure
Left ventricular ejection fraction 0.4, with need
for diuretic and/or angiotensin-converting
enzyme inhibitor therapy, requiring
hospitalization.
Need for new cardiac
revascularization
procedure
Any new surgical or percutaneous
revascularization procedure on a treated
vessel.ithin the follow-up period, only the first event was
C
Yonsidered. Kaplan-Meier analysis was used to study patient
urvival and event-free status, using the log-rank test (Cox-
antel) to ascertain differences between groups. All data
ere analyzed using STATISTICA 6.0 (StatSoft Inc.,
ulsa, Oklahoma).
esults
atient population. In all, 672 consecutive patients were
creened. An RCRI 2 was found in 464 patients and
ollowed the published guidelines for pre-operative risk
ssessment (11). The remaining 208 patients, with an RCRI
2, were enrolled and randomly allocated to a selective
trategy or a systematic strategy. The selective strategy
roup (group A  103 patients) underwent a stress test
ollowed by coronary angiography if the test was positive.
he systematic strategy group (group B 105 patients) was
ssigned to outright coronary angiography, without a pre-
ious noninvasive test. Carvedilol, a nonselective beta1/
eta2-blocker with alpha-blocking activity, was used (12.5
o 25 mg twice daily) for all patients to obtain a resting heart
ate of 60 beats/min (58.1  3.8 beats/min and 57.5 
.4 beats/min in group A and group B, respectively; p 
.3): the target heart rate was achieved in 95.1% of group A
atients and in 94.3% of group B patients (p  0.8).
linical and demographic characteristics are summarized in
able 2.
arly outcome. Table 3 summarizes 30-day outcome data
or the 2 groups. In the selective strategy group A, the
oninvasive test was positive in 47 (45.6%) patients; they
nderwent coronary angiography, which demonstrated sig-
haracteristics of Patients Randomized to SelectiveGroup A) or Routine (Group B)or nary Angiography
Table 2
Char cteristics of Patients Randomized to Selective
(Group A) or Routine (Group B)
Coronary Angiography
Clinical Variables
Group A
(n  103)
Group B
(n  105) p Value
Age, yrs 73.1 4.3 74.4 5.3 NS
Men 82.6 75.0 NS
NYHA functional class III or IV 21 (20.4) 27 (25.7) 0.5
CCS class III or IV 23 (22.3) 26 (24.8) 0.8
Peripheral arterial disease
Aortoiliac obstruction/stenosis 65 (63.1) 61 (58.1) NS
Abdominal aortic aneurysm 38 (36.9) 44 (41.9) NS
Diabetes mellitus 40 (38.8) 39 (37.1) NS
Hypertension 72 (69.9) 70 (66.6) NS
Ischemic heart disease 32 (31.1) 35 (33.3) NS
Previous CABG 16 (15.5) 18 (17.4) NS
Previous vascular surgery 13 (12.6) 14 (13.3) NS
CVA 18 (17.5) 22 (20.9) NS
Creatinine 1.7 mg/dl 35 (33.9) 36 (34.3) NS
Chronic obstructive pulmonary
disease
42 (40.1) 45 (42.8) NS
RCRI score 3.2 0.7 3.3 0.6 NS
ASA score 1.7 0.5 1.8 0.4 NS
alues are mean  SD or n (%).
ASA American Society of Anesthesiologists; CABG coronary artery bypass graft surgery; CCS
anadian Cardiovascular Society; CVA cerebrovascular accident; NS not significant; NYHA New
ork Heart Association; RCRI revised cardiac risk index.
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Coronary Angiography Before Vascular Surgery September 8, 2009:989–96ificant coronary artery lesions in 46 (44.7%). Myocardial
evascularization was performed in 42 (40.8%) such pa-
ients, either by percutaneous coronary intervention (n 
0, 29.1%) or by OPCABG (n 12, 11.6%), as appropriate
22) (Table 4); it was staged in 37 (35.9%) patients and
ombined in 5 (4.9%), with an operative mortality of 2.4%
1 patient died of cardiogenic shock). Of the 41 surviving
atients undergoing myocardial revascularization, 3 did not
ubsequently undergo vascular surgery: 1 patient died during
he interprocedure interval of cardiac-related causes, and 2
eclined surgery. Thirty-eight patients underwent the
lanned vascular operation within 2 months, with no
perative mortality. The remaining 61 patients (56 with
egative noninvasive tests, 1 with negative coronary angiog-
aphy, and 4 with coronary anatomy not amenable to
evascularization) directly underwent the planned vascular
peration. In this subgroup, there were 5 operative deaths (5
f 61, 6.5%), all cardiac related.
30-Day OutcomeTable 3 30-Day Outcome
Group A
(n  103
Patients with CAD 46 (44.7)
Myocardial revascularization 42 (40.1)
Major vascular surgery 99 (96.1)
Previous myocardial revascularization* 38 (36.9)
Interprocedure lost patients* 4 (3.9)
Cardiac mortality 7 (6.8)
Myocardial revascularization related 1 (1.0)
Interprocedure 1 (1.0)
Vascular surgery related 5 (4.8)
MACE 5 (4.8)
Myocardial infarction 4 (3.9)
Cerebrovascular accident 1 (1.0)
MACE, including cardiac mortality 12 (11.7)
LOS, days 7.5 2.5
Values are mean  SD or n (%). *See the section “Results: Early Outc
CAD coronary artery disease; CI confidence interval; LOS length
oronary Angiography Resultsnd Revascularization ProceduresTable 4 C ronary Angiography Resultsand Revascularization Procedures
Group A
(n  42)
Group B
(n  61) p Value
Number of diseased vessels
1 vessel 11 (26.2) 17 (27.9) 0.9
LAD 9 (21.5) 13 (21.3)
2 vessels 15 (35.7) 17 (27.9) 0.8
3 vessels or more 16 (38.1) 27 (44.3) 0.5
Left main disease 4 (9.5) 8 (13.1) 0.8
PCI 30 (71.4) 32 (52.5) 0.08
Complete revascularization 30 (100) 31 (96.8)
OPCABG 12 (28.6) 29 (47.5) 0.08
Complete revascularization 11 (91.7) 29 (100)
alues are n (%).t
LAD  left anterior descending coronary artery; OPCABG  off-pump coronary artery bypass
raft surgery; PCI  percutaneous coronary intervention.Overall, of the 103 group A patients, 99 (96.5%) under-
ent vascular surgery with an intention-to-treat hospital
ortality (including patients not undergoing vascular sur-
ery or patients who died during the interprocedure inter-
al) of 6.8% (7 of 103 patients).
In the systematic strategy group B, 65 (61.9%) patients
howed significant coronary stenosis (p  0.02; odds ratio:
.07; 95% confidence interval: 1.1 to 3.9, vs. group A). No
ajor complications related to coronary angiography were
bserved. Of the 65 patients with coronary angiography
ositive for CAD, 61 (58.1%) had indications for myocar-
ial revascularization, either percutaneous coronary inter-
ention (n  42, 40.0%) or OPCABG (n  19, 18.1%), as
ppropriate (22) (Table 4). Staged myocardial revascularization
as performed in 50 (47.6%) patients, and a combined
pproach was carried out in 11 (10.5%). One in-hospital death
as observed (1.6%). Forty-four patients (41.9%), 40 with
bsence of CAD at coronary angiography and 4 with CAD
eemed unfit for myocardial revascularization, directly under-
ent the planned vascular operation. There were no hospital
eaths. Four patients who had undergone prior myocardial
evascularization did not subsequently undergo vascular sur-
ery: 1 patient died during the interprocedure interval of
ardiac-related causes, and 3 patients declined surgery. The
emaining 56 patients underwent the planned vascular opera-
ion within 2 months, with no 30-day mortality.
Overall, of the 105 group B patients, 100 (94.3%)
nderwent vascular surgery with an intention-to-treat hos-
ital mortality of 1.9% (2 of 105 patients, p  0.08, vs.
roup A).
The overall incidence of MACE, including cardiac mortal-
ty, was higher in group A (n  12) than in group B (n  5,
 0.1), although not reaching statistical significance, whereas
he length of hospital stay was significantly higher in group A
Group B
(n  105) p Value OR (95% CI)
65 (61.9) 0.02 2.07 (1.1–3.9)
61 (58.1) 0.01 2.01 (1.1–3.6)
100 (95.2) 0.9 —
56 (53.3) 0.02 0.5 (0.3–0.9)
4 (3.8) 0.8 —
2 (1.9) 0.08 —
1 (0.9) 0.7 —
— 0.5 —
1 (0.9) 0.1 —
3 (2.8) 0.7 —
2 (1.9) 0.6 —
1 (0.9) 0.5 —
5 (4.8) 0.1 —
6.8 2.1 0.03 —
or explanation.
ital stay; MACEmajor adverse cardiovascular event; OR odds ratio.)han in group B patients (p  0.03).
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September 8, 2009:989–96 Coronary Angiography Before Vascular Surgeryollow-up. Follow-up ranged from 36 to 95 months, with
mean of 58  17 months. No patients were lost to
ollow-up. No difference was observed in functional status:
0 (10.6%) patients and 14 (14.1%) patients were in NYHA
unctional class III or IV in group A and B, respectively
p  0.6); a significantly better outcome was observed with
espect to CCS anginal class: there were 29 (30.8%) patients
Figure 1 Cumulative Survival
Cumulative survival for patients (pts) of group A (dashed line [n  103]) and group
Figure 2 Freedom From Major Cardiac Events
Freedom from major adverse cardiac events (MACE) for patients (pts) of group A (sn group A and 17 (17.2%) patients in group B (p  0.03)
n CCS class 2.
Survival and freedom from any cardiac-related event,
ncluding mortality, are shown in Figures 1 and 2, respec-
ively. At Kaplan-Meier survival analysis, there was a
ignificant difference between group A and group B survival
p  0.01) and freedom from any cardiac-related event
lid line [n  105]), intention-to-treat.
ne [n  103]) and group B (dashed line [n  105]), intention-to-treat.B (soolid li
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Coronary Angiography Before Vascular Surgery September 8, 2009:989–96ncluding mortality (p  0.003). For this end point, the
-year freedom from events was 69.6  4.7% for group A
nd 86.6  3.6% for group B, with an absolute risk
eduction of 16.7%, corresponding to a relative risk reduc-
ion of 59.4% (95% confidence interval: 1.4 to 6.8; p 
.04); the 8-year freedom from events was 53.5  6.3% for
roup A and 77.5 4.8% for group B, with an absolute risk
eduction of 19.8%, corresponding to a relative risk reduc-
ion of 53.6% (95% confidence interval: 1.4 to 5.7; p 
.002).
iscussion
or patients in preparation for major vascular surgery, the
resent study shows that a strategy of “prophylactic” coro-
ary artery angiography for all patients at medium-high
isk, followed by coronary revascularization as needed, is
ore effective in curbing the rate of post-operative cardiac
vents and death than is a conservative strategy of coronary
ngiography and revascularization performed on the basis of
positive noninvasive test. Furthermore, the benefits of this
ystematic approach extended well beyond the perioperative
hase, as the rate of cardiac events at late follow-up was
ne-half of that among patients for whom coronary angiog-
aphy was performed only in selected cases.
There is general agreement that CAD remains the major
ause of perioperative mortality after major vascular surgery
6,23–25). The pre-operative screening of patients in need
f major vascular surgery is therefore of paramount impor-
ance to decrease surgical risk and obtain good long-term
esults. The RCRI discriminates patients with low proba-
ility (Class I and II, risk 0.4% and 0.9%) from those with
igh probability (Class III and IV, risk 6.6% and 11%) of
ajor cardiac events (26). For such patients in Class III and
V, ACC/AHA guidelines recommend pre-operative non-
nvasive cardiac evaluation (21). However, the use of non-
nvasive tests in the pre-operative assessment of these
atients may at times prove inaccurate. Bursi et al. (27)
ecently reported that, despite adherence to pre-operative
isk stratification according to the ACC/AHA guidelines,
atients undergoing elective major vascular surgery are still
t high risk of MI and death; Back et al. (28) demonstrated
hat the presence of 3-vessel angiographic CAD was an
ndependent predictor of cardiac morbidity, whereas induc-
ble ischemia by stress imaging was not. Moreover, among
ome high-risk patients, namely, patients undergoing liver
r kidney transplantation, a systematic coronary angiogra-
hy approach may be of benefit (29,30).
A meta-analysis involving 8,008 subjects, showed a 0.5%
f annualized event rate of MI or cardiac death and a 1.25%
nnualized event rate of myocardial revascularization or
nstable angina after a normal myocardial perfusion stress
est (31). Although myocardial perfusion testing provides
ccurate clinical information, there are instances in which
otentially life-threatening CAD may be present, even
hough there are no significant abnormalities on the merfusion-imaging test (32). Diamond et al. (33) recently
eported an incidence of 29% of significant CAD (9.1% left
ain and/or 3-vessel disease) among patients with normal
yocardial perfusion test who subsequently underwent cor-
nary angiography within 6 months from the stress test.
oninvasive testing as a tool to predict and reduce pre-
perative risk may rest with the relative suboptimal perfor-
ance in particular population. Patients with 1-vessel CAD
ften exhibit negative stress tests (34). Furthermore, among
he elderly, a negative and/or an equivocal noninvasive test
oes not necessarily exclude an important CAD involve-
ent (35). Finally, vascular patients are often unable to
erform adequate exercise, they may also have concomitant
ulmonary morbidity that prevents executing stress echo-
ardiography, and they are less likely to be left off drugs to
ndergo diagnostic testing. The results of the present
tudy lend support to this interpretation as we observed
hat in the systematic strategy patients, a significantly
reater proportion underwent coronary revascularization
efore vascular surgery compared with selective strategy
atients. It is unlikely that we inadvertently selected 2
roups with significantly different prevalences of CAD,
ince patients were allocated to either strategy on a
andom basis, and since baseline characteristics were
imilar in the 2 groups; a more likely explanation is that
oninvasive testing missed a substantial portion of pa-
ients with CAD.
omparison with previous studies. In spite of the obvious
linical relevance of the issue, there is a relative paucity of
ata to precisely address the role of coronary angiography in
reparation for a major vascular intervention. That aggres-
ive treatment of CAD before vascular surgery may reduce
he coronary risk and improves long-term outcomes has
een suggested by several studies (7,8,36); however, they
ere retrospective, nonrandomized reports. In contrast, the
ARP trial (9) randomized 510 patients, and showed that
re-operative coronary artery revascularization before an
lective vascular operation does not improve long-term
ost-operative outcome. However, it should be noted that
he vast majority of patients in the CARP trial had
ingle-vessel or 2-vessel disease, with normal left ventricular
jection fraction. For these patients, adequate cardioprotec-
ion can be expected by medical therapy (37). Hence, the
ECREASE (Dutch Echocardiographic Cardiac Risk
valuation Applying Stress Echo Study Group)-V random-
zed pilot study was more recently performed in patients
ith extensive stress-induced myocardial ischemia; in this
tudy, also, pre-operative coronary revascularization was not
ssociated with an improved outcome (10). This trial,
owever, considers as end points only cardiac death and MI
nd excludes all cardiovascular events (cerebrovascular acci-
ent, congestive heart failure) and repeated revasculariza-
ion, and patients were followed up for only 1 year after
urgery, whereas in our study, both survival and freedom
rom MACE curves start to diverge from 2 years. Further-
ore, the DECREASE-V study randomized a highly
s
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ularization without exception, and had an extremely high
ortality and MI rate. Moreover, both the CARP study and
he DECREASE-V trial recommended coronary angiogra-
hy only on the basis of the presence of ischemia on a
oninvasive stress imaging study: patients with CAD but
egative or limited ischemia at stress testing may have been
eft out of coronary revascularization, thus reducing its
ossible benefits.
The issue is, therefore, still much debated to this very day
38–40). To our knowledge, ours is the first study that
rospectively and randomly evaluates “all comers” for pro-
hylactic coronary angiography, extending the observations
nto follow-up for several years.
tudy limitations. The present study randomly allocated
08 patients, and therefore results cannot be immediately
xtended to the large population of patients at medium-
igh risk who need vascular surgery. As demonstrated by
thers (9), however, because of the obvious difficulties in
andomizing this type of patient, it is not easy to recruit
ubstantially larger populations. Another limitation is the
ack of blinding of investigators that is inherent to the trial
esign, and the lack of an independent events adjudication
ommittee. However, we believe that the choice of the end
oints of death and major cardiac events helps minimize this
imitation.
mplications. In addition to the possibility of reducing
erioperative risk, a strategy of systematic coronary angiog-
aphy for patients at medium-high risk who are candidates
or major vascular surgery may also have additional benefi-
ial effects, thus improving the AHA/ACC guidelines.
oronary angiography precisely assesses coronary anatomy,
llowing the physician to treat more effectively the under-
ying CAD as well as coronary risk factors, and that
onceivably will translate into better long-term secondary
revention of cardiac events and into a patient’s increased
ompliance with and adherence to life-long medical multi-
herapy. In addition, the reduced length of hospital stay
onnected with the vascular surgery procedure and the
ossibility of performing in the same session both coronary
nd vascular angiography may also help defray higher costs
onnected with performing more coronary angiographies; in
his respect, one should also factor in the further cost-
ffectiveness advantage of not performing noninvasive
valuation.
onclusions
atients at medium-high risk of cardiovascular events
cheduled to undergo major vascular surgery, and in whom
oronary angiography was systematically performed as part
f their pre-operative workup, scored significantly better
han patients in whom coronary angiography was selectively
erformed only on the basis of positive noninvasive tests.
ur data indicate that the advantages of such a systematicpproach may significantly offset its disadvantages, and call
1or larger, multicenter trials to thoroughly investigate this
mportant clinical issue.
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